Pre-made Apamistamab benchmark antibody ( Whole mAb Radiolabelled, anti-PTPRC therapeutic antibody, Anti-B220/CD45/CD45R/GP180/L-CA/LCA/LY5/T200 Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-029
Pre-Made Apamistamab biosimilar, Whole mAb Radiolabelled, Anti-PTPRC Antibody: Anti-B220/CD45/CD45R/GP180/L-CA/LCA/LY5/T200 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
The investigational drug 131-I apamistamab is a protein combined with a radioactive form of iodine, which gives off a small amount of radiation. ... It kills them, which prevents them from making other proteins associated with the side effects seen in some people who receive CAR T-cell therapy.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Apamistamab biosimilar, Whole mAb Radiolabelled, Anti-PTPRC Antibody: Anti-B220/CD45/CD45R/GP180/L-CA/LCA/LY5/T200 therapeutic antibody|
|Format||Whole mAb Radiolabelled|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Actinium Pharmaceuticals;Fred Hutchinson Cancer Research Center|
|Conditions Active||Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma|
|Conditions Discontinued||Hodgkin's disease;Non-Hodgkin's lymphoma|